Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit

• DOI: 10.20944/preprints202411.0926.v1
• Publication Date: 2024-11-19T01:21:57Z
• Authors: Niki Dermitzaki; Foteini Balomenou; Dimitra Gialamprinou; Vasileios Giapros; Dimitrios Rallis; Maria Baltogianni
• Keywords: Echinocandins

The neonatal intensive care unit (NICU) population, especially low birth weight and critically ill neonates, is at risk of invasive Candida infections, which are associated with high mortality rates unfavorable long-term outcomes. timely initiation an appropriate antifungal treatment has been demonstrated to enhance the prognosis. Factors that should be considered in choice agent include causative strain, presence location deep tissue infection, previous use prophylaxis, implanted devices. Amphotericin B fluconazole, first-line drugs for candidiasis, not always suitable due several limitations terms efficacy adverse effects. Therefore, alternative antifungals have studied used neonates when conventional ineffective or contraindicated. This review aims provide overview current literature regarding echinocandins population. three echinocandins, micafungin, caspofungin, anidulafungin, share characteristics make them useful including activity against a wide range strains biofilms favorable safety profile.